Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
11:00pm, Wednesday, 06'th May 2026
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
04:25pm, Wednesday, 06'th May 2026
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript
10:41pm, Tuesday, 05'th May 2026
Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
07:05pm, Tuesday, 05'th May 2026
Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago.
Cytokinetics Announces Proposed Public Offering of Common Stock
04:15pm, Tuesday, 05'th May 2026
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 milli
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Tuesday, 05'th May 2026
U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maxi
Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript
Cytokinetics heart disease drug meets main goals in late-stage study
07:35am, Tuesday, 05'th May 2026
Cytokinetics said on Tuesday its experimental drug to treat a type of heart disease met the main goals in a late-stage trial.
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints
Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announce
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
09:30am, Sunday, 03'rd May 2026
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher.
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
07:30am, Tuesday, 28'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Co
Cytokinetics to Announce First Quarter Results on May 5, 2026
04:00pm, Tuesday, 21'st Apr 2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Monday, 20'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
02:40pm, Friday, 17'th Apr 2026
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
